Landauer — Q3 FY2013 Earnings Presentation
23 slides from Landauer's earnings presentation, Aug 6, 2013
Slide 1: Safe Harbor Statement
2 Safe Harbor Statement Some of the information shared here (including, in particular, the section titled “Fiscal 2013 Outlook”) constitutes forward - looking statements that are based on assumptions and involve certain risks and uncertainties . These include the following, without limitation : assu
Slide 2: Landauer Today: The Global Leader in Radiation Science and Services
Financial Highlights Three Operating Segments Diverse Markets Served Business Facts Business Facts • Based in Glenwood, IL • Founded in 1954 • Approximately 550 employees • Global Platform and Infrastructure • 78,000 annual customers served; 1.7 annual individuals served • 94%+ Customer retention ra
Slide 3: Radiation Management is Becoming More Complex
Radiation Management is Becoming More Complex Advanced imaging and treatment choices, healthcare consolidation and tougher regulations and standards are raising the bar for radiation safety Evolving Treatments Advanced radiation treatment choices and consumerism Healthcare Consolidation Acquisitions
Slide 4: Radiation Risk Not Managed Consistently
Radiation Risk Not Managed Consistently Healthcare Systems do not have a single expert focused on radiation risk across all locations, departments and modalities • Radiation injury and even death • Lawsuits $100K - $15M+ • Violations, delays in patient care, & poor PR • Risk to pregnant & at - risk
Slide 5: Building an Integrated Radiation Safety Solution
Building an Integrated Radiation Safety Solution Occupational Monitoring/Patient Monitoring Market Opportunity: $ 365M “ Dose to Worker ” Radiation Measurement Market Share Leader/Stable Business Market Share Leader/Fragmented Competition Adjacent Product Segment/High Margin Consumables Core Busines
Slide 6: Attractive Niche Business Model – Annuity Focused
Attractive Niche Business Model – Annuity Focused Hospitals Nuclear Power Medical Imaging Industry Radiation Measurement Therapy Imaging Commissioning Medical Physics Image Guided Procedures Radiation Therapy Medical Products Strong, Stable Core Business with Growth Opportunities Complementary Growt
Slide 7: Driving Strong Cash Flows
* Note: Fiscal 2009 Net Income excludes $1.8M after - tax impact of charges Driving Strong Cash Flows… Revenue, Net Income & Cash Flow from Operations ($ in Millions) 8 75.2 79.0 82.1 90.0 93.8 114.4 120.5 152.4 19 20 21 23 25* 24 25 19 21 24 28 35 31 26 31 36 28% 30% 34% 39% 33% 23% 26% 24% 0% 10%
Slide 8: Generating Robust Dividend Payments
…and Generating Robust Dividend Payments “Best In Class” Dividend Yield 0.0% 0.5% 1.0% 1.5% 2.0% 2.5% 3.0% 3.5% 4.0% 4.5% 5.0% $0.60 $0.80 $1.00 $1.20 $1.40 $1.60 $1.80 $2.00 $2.20 $2.40 Sep - 03 Sep - 04 Sep - 05 Sep - 06 Sep - 07 Sep - 08 Sep - 09 Sep - 10 Sep - 11 Sep - 12 Annual Dividend Per Sha
Slide 9: Executing a Successful Strategy
Executing a Successful Strategy Optimize Core Competitive Growth Strategic Expansion Deliver Sustainable Long Term Growth and Maximize Total Shareholder Returns 10
Slide 10: Radiation Measurement Strategic Initiatives
Radiation Measurement Strategic Initiatives □ Management/Structure • New Segment President Q3 FY 2012 □ IT Platform Enhancement • Went live in July 2012 • Order to Cash Functionality • Full System Functionality, Declining Stabilization Expenses □ Global Shared Services • Sales/Marketing • Manufactur
Slide 11: Medical Physics Strategic Initiatives
Medical Physics Strategic Initiatives □ Management/Structure • New Segment President Q4 FY 2012 □ Profitability Improvement Initiatives • Operating Loss (FY 2010 & 2011) • Operating Income FY 12: 6.5% of Revenues • Operating Income: - YTD FY13: 11.3% of Revenues - Q3 FY13: 12.7% of Revenues □ Hospit
Slide 12: Medical Products Strategic Initiatives
Medical Products Strategic Initiatives □ Management/Structure • New Segment President Q1 FY 2013 • GM and Product Development Experience • J&J, Baxter, and Cardinal • New VP of Sales 2Q’13 • Med Device exp. • Telesales exp. – 7 yrs • New Senior VP of Business Development • Former Precino Med Preside
Slide 13: Q3 FY 2013 Highlights
Q3 FY 2013 Highlights Radiation Measurement ▪ Top Line Initiatives ▪ Bottom Line Initiatives Strategic Expansion • Patient monitoring – new Microstar system introduction in Q4 FY 2013 • Next generation dosimetry platform – R&D development Competitive Growth • Group purchasing changing dynamics • Rad
Slide 14: Q3 FY 2013 Highlights: Innovative New Products
Q3 FY 2013 Highlights Innovative New Products Radwatch “Cloud based Data Management” http:// youtube/ETsvfary6m0 Radiation Measurement 15 MicroStar 2 “Patient Dose Data Management”
Slide 15: Financial Overview
Financial Overview Respect Innovation Honesty Reliability
Slide 16: Landauer Financial Overview
Landauer Financial Overview ($ in millions, FYE 9/30) Revenue $93.8 $114.4 $120.5 $ 152.4 $ 152.5* 2009 2010 2011 2012 2013E ($ in millions, FYE 9/30) Adjusted EBITDA $45.3 $46.6 $ 48.5 $54.2 $48* 2009 2010 2011 2012 2013E ▪ Approximately 90 % of revenue derived from subscription and is recurring in
Slide 17: 3Q FY13 Financial Highlights
3Q’ FY13 Financial Highlights Adjusted EBITDA ▪ Revenue of $ 36 . 6 million in the third quarter of fiscal 2013 ▪ Goodwill impairment charge of $ 22 . 7 million related to the carrying value of the Medical Products business ▪ Operating loss of $ 16 . 8 million includes goodwill impairment charge ( $
Slide 18: FY 2013 Outlook vs. FY 2012 Actual
FY 2013 Outlook vs. FY 2012 Actual Fiscal Year 2013 Outlook - Updated ▪ Expected Revenue $150 to $155 million, which includes a full year of contributions from IZI Medical Products acquisition, versus 10.5 months in fiscal 2012 ▪ Adjusted EBITDA of $47 to $49 million ▪ Net Income of $18.5 to $ 20.5
Slide 19: Dividend Policy
20 Dividend Policy ▪ Board of Directors declared a regular quarterly cash dividend of $0.55 per share for the third quarter of fiscal 2013 – This represents an annual rate of $2.20 per share, consistent with fiscal 2013 levels – For the t hird fiscal quarter, the dividend was paid on July 3 , 2013 t
Slide 20: Appendix
Appendix Respect Innovation Honesty Reliability
Slide 21: Landauer Corporate Evolution
Landauer, Inc. is a recognized leader in personal and environmental radiation measurement and monitoring, outsourced medical physics services and high - quality medical consumable accessories LDR Corporate Evolution InLight product technology released Acquired IZI Medical Products: Genesis of Medica
Slide 22: New IT Platform Enhancement Expenses
23 New IT Platform Enhancement Expenses Depreciation / Steady State / Customer Service / Implementation / Stabilization expenses: ― Total FY 2013 vs. FY 2012 $ 4.3 million increased expense over prior year (previously $4.4 million) • Depreciation, additional $2.4 million » Split between COG’s ($1.
Slide 23: IT Platform Accomplishments
• Customer Records - o ver 500M records migrated from IBM legacy system to new IT System platform • LDR Data Center Co - location Strategy – Phase 1.0 (FY12), Phase 2.0 (FY13). Disaster Recovery / • Redundancy / Risk Mitigation: total investment to date $3.4M • Landauer Databases – over 325% increas